Search Results for 'istent trabecular micro-bypass'
-
Data Show Glaukos’ iStent inject Delivers Greater IOP Reduction vs. iStent
iStent inject achieved greater absolute IOP declines with 93 percent of subjects medication-free vs. 76 percent of iStent subjects.Business Wire 11.20.19
-
Study Confirms Significant Medication Reduction After Implantation of Glaukos iStent inject
iStent inject achieved 42 percent reduction in Mean IOP to 14.6 mmHg and 82 percent reduction in mean medications to 0.55 at three years postoperative.Business Wire 07.23.19
-
Glaucoma Study Confirms Long-term Efficacy, Safety of Glaukos iStent Implantation
At five years postoperative, mean IOP decreased 38 percent to 14.7 mmHg and topical ocular hypotensive medication use fell 75 percent.Business Wire 04.24.19
-
Study Shows Long-Term Titrated IOP Control With Glaukos iStent Trabecular Micro-Bypass Stents
Data reveal 30 percent to 43 percent reductions in unmedicated mean IOP for single or multiple iStent implantations.Business Wire 03.23.18
-
Study: Glaukos iStent Trabecular Micro-Bypass Stent Reduces IOP, Lowers Medication Burden
Combined with cataract surgery, iStent achieved a 28 percent reduction in mean medication use.Business Wire 03.01.18
-
Glaukos to Begin Randomized U.S. IDE Pivotal Clinical Trial for the iStent SA System
Trial will enroll Pseudophakic Glaucoma subjects to assess the device’s safety, efficacy for reducing elevated IOP.Business Wire 01.22.18
-
Glaukos Issued New U.S. Patent
Latest patent covers ocular devices and methods of surgically implanting them.Business Wire 01.03.18
-
Combining Implantation of Glaukos iStent, Topical Travoprost Reduces IOP
After 18 months of follow-up, mean IOP declined 35 percent to 12.9 mm Hg.Business Wire 07.13.17
-
Study Reveals Potential Cost Efficiency of Using Glaukos iStent to Treat Elevated IOP
Data show cumulative cost at five years was lowest for two-stent procedure compared to laser treatment or topical medication.Business Wire 06.06.17
-
Diagnostics
Glaukos Completes Patient Enrollment in Phase II Clinical Trial for iDose Travoprost Implant
Trial to assess implant’s preliminary safety and efficacy for reduction of elevated intraocular pressure.Business Wire 05.17.17
-
Study Shows Two Glaukos Micro-Bypass Stents, Topical Medication Reduce Intraocular Pressure
Data indicate 86 percent of eyes had an IOP of less than 18 mm Hg three years after the procedure.Business Wire 04.20.17
-
Study Evaluates a Single Glaukos iStent Trabecular Micro-Bypass Stent as a Standalone Procedure
Case series of 42 pseudophakic eyes shows mean medicated intraocular pressure fecrease of 6.64 mm Hg.Business Wire 12.14.16
-
Glaukos Stent Reduced IOP and Medication Use in Predominately Hispanic Glaucoma Patients
Clinical study shows mean IOP of 12.9 mm Hg and 61 percent reduction in mean medication burden.Business Wire 11.11.16
-
Study Shows Favorable Three-Year Results of Two Glaukos iStent Trabecular Micro-Bypass Stents
Patients who received two iStents achieved 43 percent reduction in mean intraocular pressure.Business Wire 09.29.16
-
Glaukos iStent Trabecular Micro-Bypass Stent Approved in Japan
Approved by the MHLW for use in combination with cataract surgery.Glaukos Corporation 03.30.16
